

# Bringing Description Bringing to patients with depression



# Hope is knowing remission from depression is possible

Depression is a serious illness that affects approximately 350 million people worldwide. <sup>1</sup> While medications may help manage symptoms, many patients are not satisfied with the results they get from standard drug therapy. NeuroStar TMS Therapy® is a novel approach to achieving remission in depression that is bringing new hope to patients every day.

"I can't begin to tell you what a difference TMS has made in my life. I am just so much happier."

- Susan, 58 years old

#### NeuroStar TMS Therapy for depression

- For patients who have not benefited from prior antidepressant medications
- Free from side effects often associated with antidepressant medications<sup>2-4</sup>
- Safe, effective therapy that can be conducted right in the doctor's office<sup>2</sup>

# Hope with a proven, non-drug therapy

NeuroStar TMS Therapy® uses highly focused magnetic pulses to stimulate areas of the brain that may be underactive in patients with depression.



- Magnetic pulses target key areas of the brain<sup>2</sup>
- Technology is similar to that of magnetic resonance imaging (MRI)
- Each in-office treatment takes 37 minutes
- Patients receive therapy 5 days a week, for 4 to 6 weeks
- During treatment, patients are awake and alert; they can go back to their normal activities immediately afterward

## NeuroStar TMS Therapy<sup>®</sup> is safe and effective

## Many patients experience significant benefits<sup>5</sup>

- 1 in 2 patients improved significantly
- 1 in 3 patients were free of depression symptoms
- Durable symptom relief over 12 months
  - depressed I wasn't able to function.
    After six weeks of NeuroStar TMS
    Therapy, I was back to work; I was feeling great; I was enjoying my kids again and I had my life back.

- Craig, 38 years old

## Demonstrated track record of experience

- FDA cleared since 2008 for the treatment of patients with major depression who failed to benefit from antidepressant medication
- Clinically proven in multiple trials with 800 depression patients<sup>5-7</sup>
- Over 18,000 patients treated<sup>4</sup>
- Nearly 600 NeuroStar physicians provide therapy worldwide

## Is NeuroStar TMS Therapy® right for you?

If you answer agree to any of these questions, ask your doctor about NeuroStar TMS Therapy.

Depression symptoms have interfered with my daily life.  Agree Disagree
I am not satisfied with the results I get from depression medication.  Disagree
I have had, or have worried about, side effects from depression medication.
I am interested in a proven, non-drug therapy for depression.   Disagree

## Remission from depression is possible.

### Talk to a NeuroStar physician today.

#### Indication

NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

A doctor can help decide if NeuroStar TMS Therapy is right for you.

#### Important Safety Information

NeuroStar TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head.

The most common side effect is pain or discomfort at or near the treatment site. There is a rare risk of seizure associated with the use of TMS. You should talk with a NeuroStar physician to determine if TMS Therapy may be right for you.

In a randomized controlled trial, patients receiving active NeuroStar TMS Therapy were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05).8

#### References:

World Health Organization. Depression fact sheet No.369. http://www.who.int/mediacentre/factsheets/fs369/en/index.html. Accessed February 27, 2013.
 NeuroStar Prescribing Information. 3. Janicak PG, et al. (2008) J Clin Psychiatry, 69(2):222-232.
 Data on file. Neuronetics, Inc. 5. Carpenter LL, et al. (2012) Depress Anxiety, 29(7):587-596.
 O'Reardon JP, et al. (2007) Biol Psychiatry, 62(11):1208-1216.
 George MS, et al. (2010) Arch Gen Psychiatry, 67(5):507-516.
 Demitrack MA, Thase ME. (2009) Psychopharmacol Bull, 42(2):5-38.

NeuroStar.com

TheDepressionHopeCenter.com

